Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Cash (2020 - 2025)

Historic Change in Cash for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $21.8 million.

  • GeneDx Holdings' Change in Cash rose 110176.02% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year increase of 22948.72%. This contributed to the annual value of -$14.5 million for FY2024, which is 6156.24% up from last year.
  • Latest data reveals that GeneDx Holdings reported Change in Cash of $21.8 million as of Q3 2025, which was up 110176.02% from -$25.6 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Change in Cash peaked at $424.8 million during Q3 2021, and registered a low of -$93.3 million during Q3 2022.
  • Over the past 5 years, GeneDx Holdings' median Change in Cash value was -$25.6 million (recorded in 2025), while the average stood at -$1.2 million.
  • Data for GeneDx Holdings' Change in Cash shows a peak YoY increase of 3716796.72% (in 2021) and a maximum YoY decrease of 564563.38% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows GeneDx Holdings' Change in Cash stood at -$60.7 million in 2021, then decreased by 11.07% to -$67.4 million in 2022, then skyrocketed by 118.36% to $12.4 million in 2023, then surged by 120.67% to $27.3 million in 2024, then dropped by 20.03% to $21.8 million in 2025.
  • Its Change in Cash was $21.8 million in Q3 2025, compared to -$25.6 million in Q2 2025 and $14.5 million in Q1 2025.